{
  "ptid_time": "005_S_4185_2017-09-21",
  "img_path": "/data/qiuhui/data/adni/images/005_S_4185/2017-09-21/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 88,660 mm³, 88.6% above the reference mean. With a Z-score of 2.57 (99.5th percentile), this represents significant enlargement; hippocampal volume measures 5,626 mm³, 19.3% below the reference mean. With a Z-score of -1.66 (4.8th percentile), this represents moderate atrophy; whole brain volume measures 905,453 mm³, 12.0% below the reference mean. With a Z-score of -1.58 (5.8th percentile), this represents moderate atrophy; entorhinal cortex volume measures 3,012 mm³, 24.1% below the reference mean. With a Z-score of -1.58 (5.7th percentile), this represents moderate atrophy; fusiform gyrus volume measures 16,308 mm³, 9.7% below the reference mean. With a Z-score of -0.84 (20.0th percentile), this represents normal volume ; middle temporal gyrus volume measures 18,660 mm³, 7.5% below the reference mean. With a Z-score of -0.67 (25.1th percentile), this represents normal volume . ",
  "text_data": "Age is 86.4 years. Gender is Male. Education: 20 years. MMSE: 29.0. MoCA: 22.0. Logical Memory: 11.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant ventricular enlargement (consistent with atrophy) and moderate atrophy in the hippocampus, whole brain, and entorhinal cortex—all key regions affected in Alzheimer's disease. Despite the high MMSE (29), the MoCA (22) suggests mild cognitive impairment, and the structural changes align with early neurodegeneration.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)**  \n**Confidence:** **Medium** (High structural evidence but conflicting cognitive scores—MMSE near-normal, MoCA borderline impaired. APOE4-negative status reduces but doesn't rule out AD-related MCI.)  \n\n*Note:* The discrepancy between MMSE (insensitive to early deficits) and MoCA (more sensitive) is common in MCI. The atrophy pattern is concerning for prodromal AD, but clinical correlation (e.g., longitudinal decline, biomarkers) would strengthen confidence.",
  "timestamp": "2025-07-25T21:21:06.955385"
}